Ial adverse drug events in frail elderly inpatients and outpatients. Am
Ial adverse drug events in frail elderly inpatients and outpatients. Am J Overall health Syst Pharm 2001, 58(17):1622626. Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ: DNMT3 site inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother 2010, 44(six):95763. Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D: Potentially inappropriate medicines defined by STOPP criteria along with the danger of adverse drug events in older hospitalized patients. Arch Intern Med 2011, 171(11):1013019. Fialova D, Topinkova E, Gambassi G, Finne-Soveri H, Jonsson PV, Carpenter I, Schroll M, Onder G, Sorbye LW, Wagner C, Reissigova J, Bernabei R: Potentially inappropriate medication use amongst elderly home care patients in Europe. JAMA 2005, 293(11):1348358. Carey IM, De Wilde S, Harris T, Victor C, Richards N, Hilton SR, Cook DG: What variables predict potentially inappropriate main care prescribing in older men and women Analysis of UK main care patient record database. Drugs Aging 2008, 25(eight):69306. Bradley MC, Fahey T, Cahir C, Bennett K, O’Reilly D, Parsons C, Hughes CM: Potentially inappropriate prescribing and price outcomes for older men and women: a cross-sectional study making use of the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol 2012, 68(ten):1425433. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K: Potentially inappropriate prescribing and expense outcomes for older individuals: a national population study. Br J Clin Pharmacol 2010, 69(five):54352. Garc Rodr uez LAPGS: Use of the UK General Practice Research CD40 manufacturer Database for pharmacoepidemiology. Br J Clin Pharmacol 1998, 45(5):41925. Jick H, Jick SS, Derby LE: validation of details recorded on basic practitioner based computerised data resource within the Uk. BMJ 1991, 302(6779):76668. van Staa TP, Abenhaim L, Leufkens H: A study in the effects of exposure misclassification as a consequence of the time-window design in pharmacoepidemiologic research. J Clin Epidemiol 1994, 47(2):18389. Globe Well being Organisation: About the ATC/DDD program. In 2008. Out there at: whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system/. Accessed July 01 2013. Patterson SMHC, Kerse N, Cardwell CR, Bradley MC: Interventions to enhance the acceptable use of polypharmacy for older people today. Cochrane Database Syst Rev 2012, 16(five):CD008165. doi:ten.1002/14651858.CD008165.pub2. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A brand new technique of classifying prognostic comorbidity in longitudinal research: development and validation. J Chronic Dis 1987, 40(five):37383. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM: Ways to measure comorbidity:a important overview of accessible approaches. J Clin Epidemiol 2003, 56(3):22129. Khan NF, Perera R, Harper S, Rose PW: Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010, 11:1. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL: Aspirin for the principal prevention of cardiovascular events in girls and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295(three):30613. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin inside the primary prevention of cardiovascular disease in females. N Engl J Med 2005, 352(13):1293304. Hughes JD, Tanpurekul W, Keen NC, Ee HC: Minimizing the price of proton pump inhibitors by adopting greatest practice. Qual Prim Care 2009, 17(1):151. Molloy D, Molloy A, O’Loughlin C, Falconer M, Hennessy M: Ina.
